Want to see TNGX full AI Analyst Report?
TNGX Stock Chart & Stats
$24.77
$0.23(0.84%)
At close: 4:00 PM EDT
$24.77
$0.23(0.84%)
Day’s Range― - ―
52-Week Range$7.12 - $34.39
Previous CloseN/A
Volume1.26K
Average Volume (3M)3.60M
Market Cap
$3.94B
Enterprise Value$3.70B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$31.99M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 10, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding168,610,370
10 Day Avg. Volume4,079,552
30 Day Avg. Volume3,602,000
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue68.82
Enterprise Value/Gross Profit70.04
Enterprise Value/Ebitda-30.39
Forecast
1Y Price Target
$44.14Price Target Upside78.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage reduces near-term balance-sheet pressure and leaves more flexibility to fund clinical development. Compared with a heavily indebted biotechnology model, limited debt exposure lowers refinancing and interest burdens, although operating losses still require careful capital planning.
High Gross MarginThe exceptionally high gross margin indicates that revenue, where generated, has substantial contribution potential after direct costs. If clinical programs convert into broader commercial or partnership revenue, this economics could support meaningful operating leverage as the company scales.
Clinical Pipeline ValidationThe reported response rate and planned registrational study provide tangible clinical validation for vopimetostat combinations in genetically defined cancers. Progress toward a pivotal trial can concentrate resources around a lead asset and create a clearer path toward future product revenue.
Bears Say
Heavy Cash BurnSubstantial and consistently negative cash flow means Tango must continue financing research and development externally while products remain in development. Persistent burn reduces financial flexibility and makes future access to capital important for sustaining clinical progress.
Deep Operating LossesCurrent revenue is far below the cost base required to operate the company, leaving profitability highly dependent on successful clinical advancement and eventual commercialization. Continued large losses increase the time and capital needed to reach a self-funding business model.
Potential Equity DilutionA substantially expanded equity facility gives Tango access to additional funding for its development programs, but issuing shares can dilute existing ownership. The size of the authorization also underscores the company’s continuing reliance on external capital while cash generation remains negative.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $7.12 and its highest was $34.39 in the past 12 months.
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $3.94B.
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 17 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.317 by -$0.053.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 168,610,370 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.317. Following the earnings report the stock price went down -4.807%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.14 (78.21% Upside)
$44.14 (78.21% Upside)
Blogger Sentiment
Neutral
TNGX Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
209.96%
12-Months-Change
Fundamentals
Return on Equity
-25.74%
Trailing 12-Months
Asset Growth
351.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tango Therapeutics
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$44.14
▲(78.21% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
9.43% Insiders
7.85% Mutual Funds
0.71% Other Institutional Investors
68.61% Public Companies and Individual Investors